Results 151 to 160 of about 7,154 (184)

Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection

Journal of Pharmaceutical Analysis, 2023
Xiaolin Wu, Dongming Xing, Wujun Chen
exaly  

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

Clinical Infectious Diseases, 2023
Rockib Uddin, Caitlin Marino, James P Flynn   +2 more
exaly  

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs

Clinical Infectious Diseases, 2023
Louis D Saravolatz, Sharma Mamta
exaly  

Dexamethasone/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Vaccines, 2022
Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello   +2 more
exaly  

Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study

Journal of Medical Virology, 2023
Guangtong Deng, Huiyan Sun, Yating Dian   +2 more
exaly  

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance

EBioMedicine, 2023
Jonathan Daniel Ip, Allen Wing-Ho Chu, Wan-Mui Chan   +2 more
exaly  

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

New England Journal of Medicine, 2022
Weihang Bao
exaly  

Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants

Journal of Biological Chemistry, 2022
Samantha E Greasley, Stephen Noell, Olga Plotnikova   +2 more
exaly  

Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment

Clinical Infectious Diseases, 2023
Aaron F Carlin, Alex E Clark, Antoine Chaillon   +2 more
exaly